PLUR Stock Analysis: Buy, Sell, or Hold?
$1.71
-0.06 (-3.39%)
âŧ
5d:
+6.87%
30d:
-4.74%
90d:
-25.65%
WAIT
LOW Confidence
Analysis Updated: Aug 21, 2026 12:00 AM ET
Earnings: Sep 16, 2026
22d
Get Alerted When PLUR Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: PLUR is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: PLUR is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: PLUR is currently trading at $1.71, which is considered fair relative to its 30-day fair value range of $1.61 to $1.83.
Technical Outlook: Technically, PLUR is in a strong downtrend. Immediate support is located at $1.55, while resistance sits at $1.85. Short-term momentum is weak, with the stock down 3.4% recently.
Market Sentiment: PLUR scores 35/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $12.00 (+578.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, PLUR is in a strong downtrend. Immediate support is located at $1.55, while resistance sits at $1.85. Short-term momentum is weak, with the stock down 3.4% recently.
Market Sentiment: PLUR scores 35/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $12.00 (+578.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$1.61 -
$1.83
Company Quality Score
40/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
44.7%
All Signals
- NEUTRAL: Price in fair range
- BEARISH: Weak technical setup (35/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-3.4%)
- BULLISH: Trading 578.0% below Wall St target ($12.00)
- WARNING: Composite score 40/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$1.61 -
$1.83
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$1.55
Resistance Level
$1.85
Current Trend
Strong Downtrend
Technical data as of
Aug 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-0.93
Wall Street Target
$12.00
(+578.0%)
Revenue Growth (YoY)
-60.9%
Share & Embed Analysis
Last updated: August 23, 2026 7:11 PM ET
Data refreshes hourly during market hours. Next update: 8:11 PM
Data refreshes hourly during market hours. Next update: 8:11 PM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is PLUR showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$110 | 66 BUY |
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$200 | 41 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$433 | 27 SELL |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$88 | 41 HOLD |
|
BHVN
Biohaven Ltd. |
STRONG BUY
16 analysts |
$23 | 49 HOLD |